NCT02954822已完成1 期
A Randomized, Open-label, Multiple Dosing, Cross-over Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg After Oral Administration in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- AUCτ,ss for Evogliptin and Glimepiride
研究概览
简要总结
A randomized, open-label, multiple dosing, three treatment, three period, two sequence clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and glimepiride 4 mg after oral administration in healthy male subjects
详细描述
A randomized, open-label, multiple-dose, three-treatment, three-period, two-sequence, crossover study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Male Volunteers (Age: 19~45years)
- •55<Body Weight<90, 18<BMI<27
- •FPG: 70-125 mg/dL
排除标准
- •galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- •Clinically significant Medical History
- •Allergy or Drug Hypersensitivity
- •AST(SGOT), ALT(SGPT) > Upper Normal Range*1.5, eGFR<80 mL/min
- •Drink during clinical trial period
- •Smoking during clinical trial period
- •Grapefruit/Caffeine intake during clinical trial period
- •No Contraception
研究组 & 干预措施
(Group A)
Experimental
Evogliptin→Evogliptin+Glimepiride→Glimepiride
干预措施: Evogliptin→Evogliptin+Glimepiride→Glimepiride (Drug)
(Group B)
Experimental
Glimepiride→Evogliptin→Evogliptin+Glimepiride
干预措施: Glimepiride→Evogliptin→Evogliptin+Glimepiride (Drug)
结局指标
主要结局
AUCτ,ss for Evogliptin and Glimepiride
时间窗: 3 weeks
area under the concentration-time curve
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy SubjectsDrug Drug InteractionNCT05812404Daewoong Pharmaceutical Co. LTD.36
已完成
1 期
Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.HealthyNCT01808300Unimed Pharmaceuticals42
已完成
1 期
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy SubjectsDrug Drug InteractionNCT05574374Daewoong Pharmaceutical Co. LTD.36
已完成
1 期
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male SubjectsType 2 Diabetes MellitusNCT01941199Dong-A Pharmaceutical Co., Ltd.36
已完成
1 期
Study to Evaluate the Pharmacokinetics of Oral Sparsentan SuspensionHealthy SubjectsNCT05562362Travere Therapeutics, Inc.47